S&P 500   3,864.16 (+0.23%)
DOW   31,079.45 (+0.39%)
QQQ   328.69 (+0.18%)
AAPL   143.60 (+0.48%)
MSFT   232.00 (+1.08%)
FB   278.61 (+0.22%)
GOOGL   1,886.59 (-0.41%)
AMZN   3,295.11 (+0.03%)
TSLA   892.91 (+1.37%)
NVDA   543.04 (-0.57%)
BABA   263.81 (+0.93%)
CGC   33.13 (+0.67%)
GE   12.06 (+9.74%)
MU   81.73 (+0.55%)
AMD   95.17 (+1.10%)
NIO   60.20 (+0.35%)
T   29.09 (-0.07%)
F   11.28 (-0.09%)
BA   205.69 (+1.15%)
DIS   173.45 (+0.91%)
NFLX   554.76 (-0.36%)
GILD   67.50 (-0.97%)
S&P 500   3,864.16 (+0.23%)
DOW   31,079.45 (+0.39%)
QQQ   328.69 (+0.18%)
AAPL   143.60 (+0.48%)
MSFT   232.00 (+1.08%)
FB   278.61 (+0.22%)
GOOGL   1,886.59 (-0.41%)
AMZN   3,295.11 (+0.03%)
TSLA   892.91 (+1.37%)
NVDA   543.04 (-0.57%)
BABA   263.81 (+0.93%)
CGC   33.13 (+0.67%)
GE   12.06 (+9.74%)
MU   81.73 (+0.55%)
AMD   95.17 (+1.10%)
NIO   60.20 (+0.35%)
T   29.09 (-0.07%)
F   11.28 (-0.09%)
BA   205.69 (+1.15%)
DIS   173.45 (+0.91%)
NFLX   554.76 (-0.36%)
GILD   67.50 (-0.97%)
S&P 500   3,864.16 (+0.23%)
DOW   31,079.45 (+0.39%)
QQQ   328.69 (+0.18%)
AAPL   143.60 (+0.48%)
MSFT   232.00 (+1.08%)
FB   278.61 (+0.22%)
GOOGL   1,886.59 (-0.41%)
AMZN   3,295.11 (+0.03%)
TSLA   892.91 (+1.37%)
NVDA   543.04 (-0.57%)
BABA   263.81 (+0.93%)
CGC   33.13 (+0.67%)
GE   12.06 (+9.74%)
MU   81.73 (+0.55%)
AMD   95.17 (+1.10%)
NIO   60.20 (+0.35%)
T   29.09 (-0.07%)
F   11.28 (-0.09%)
BA   205.69 (+1.15%)
DIS   173.45 (+0.91%)
NFLX   554.76 (-0.36%)
GILD   67.50 (-0.97%)
S&P 500   3,864.16 (+0.23%)
DOW   31,079.45 (+0.39%)
QQQ   328.69 (+0.18%)
AAPL   143.60 (+0.48%)
MSFT   232.00 (+1.08%)
FB   278.61 (+0.22%)
GOOGL   1,886.59 (-0.41%)
AMZN   3,295.11 (+0.03%)
TSLA   892.91 (+1.37%)
NVDA   543.04 (-0.57%)
BABA   263.81 (+0.93%)
CGC   33.13 (+0.67%)
GE   12.06 (+9.74%)
MU   81.73 (+0.55%)
AMD   95.17 (+1.10%)
NIO   60.20 (+0.35%)
T   29.09 (-0.07%)
F   11.28 (-0.09%)
BA   205.69 (+1.15%)
DIS   173.45 (+0.91%)
NFLX   554.76 (-0.36%)
GILD   67.50 (-0.97%)
Log in
ASX:CURE

ETFS S&P Biotech ETF (CURE.AX) Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range
A$66.15
MA: A$66.15
A$66.15
52-Week Range N/A
Volume2,243 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

MarketRank

Overall MarketRank

0.76 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive CURE News and Ratings via Email

Sign-up to receive the latest news and ratings for CURE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ETFS S&P Biotech ETF (CURE.AX) (ASX:CURE) Frequently Asked Questions

What stocks does MarketBeat like better than ETFS S&P Biotech ETF (CURE.AX)?

Wall Street analysts have given ETFS S&P Biotech ETF (CURE.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ETFS S&P Biotech ETF (CURE.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How often does ETFS S&P Biotech ETF (CURE.AX) pay dividends? What is the dividend yield for ETFS S&P Biotech ETF (CURE.AX)?

ETFS S&P Biotech ETF (CURE.AX) declared a Final dividend on Thursday, June 25th. Stockholders of record on Wednesday, July 15th will be given a dividend of 0.039 per share on Wednesday, July 15th. This represents a dividend yield of 0.06%. The ex-dividend date is Tuesday, June 30th.
View ETFS S&P Biotech ETF (CURE.AX)'s dividend history
.

What is ETFS S&P Biotech ETF (CURE.AX)'s stock symbol?

ETFS S&P Biotech ETF (CURE.AX) trades on the ASX under the ticker symbol "CURE."

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.